Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that The Lancet and Clinical Infectious
Diseases have published online the results from the pivotal Phase 3
clinical studies of ZERBAXA (ceftolozane/tazobactam) for Injection (1
g/0.5 g) in complicated urinary tract infections (cUTI) and complicated
intra-abdominal infections (cIAI), respectively. The results will also
appear in forthcoming print issues of the journals.
Language:
English
Contact:
MerckMedia Contacts:Pam Eisele, 267-305-3558Robert Consalvo, 908-295-0928orInvestor Contacts:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more